Immunoglobulin E Sensitization to Mammalian Oligosaccharide Galactose-a-1,3 (α-Gal) Associated With Noncalcified Plaque, Obstructive CAD, ST-Segment–Elevated Myocardial Infarction

Immunoglobulin E Sensitization to Mammalian Oligosaccharide Galactose-a-1,3 (α-Gal) Is Associated With Noncalcified Plaque, Obstructive Coronary Artery Disease, and ST-Segment–Elevated Myocardial Infarction.

Stephen T. Vernon, Katharine A. Kott, Thomas Hansen, Meghan Finemore, Karl W. Baumgart, Ravinay Bhindi, Jean Yang, Peter S. Hansen, Stephen J. Nicholls, David S. Celermajer, Michael R. Ward, Sheryl A. van Nunen, Stuart M. Grieve and Gemma A. Figtree

Originally published 20 Jan 2022https://doi.org/10.1161/ATVBAHA.121.316878 Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;0:ATVBAHA.121.316878

Abstract

Background:

Treating known risk factors for coronary artery disease (CAD) has substantially reduced CAD morbidity and mortality. However, a significant burden of CAD remains unexplained. Immunoglobulin E sensitization to mammalian oligosaccharide galactose-α-1,3-galactose (α-Gal) was recently associated with CAD in a small observational study. We sought to confirm that α-Gal sensitization is associated with CAD burden, in particular noncalcified plaque. Additionally, we sort to assess whether that α-Gal sensitization is associated with ST-segment–elevated myocardial infarction (STEMI)

To read the full abstract please click here